The Research Genetic Cancer Center (RGCC) in Greece is an innovative lab which specializes in molecular and cell biology. Dr. Stegall considers their OncoStat Plus test to be an extremely powerful tool in his arsenal. The test, also referred to simply as the “Greek Test,” uses a blood sample to detect what are known as circulating tumor cells (CTCs) as well as cancer stem cells (CSCs). Both CTCs and CSCs are thought to be responsible for most of the cancer spread within the body. By detecting these cancer cells in the blood, a profile for each patient’s specific cancer cell types can be generated. These CTCs and CSCs are then tested against over 50 common chemotherapy drugs as well as approximately 50 natural substances to see which ones show the greatest potential effect on the circulating tumor cells and cancer stem cells.
The OncoStat Plus test is effective in several different patient populations:
- Patients with metastatic cancer who need to address cancer at its source
- Patients with non-metastatic cancer who want to survey their body for potential metastatic disease
- Cancer survivors who want to reduce their risk for developing a cancer recurrence in the future
Dr. Stegall orders the OncoStat Plus test as part of the initial workup. The sample is mailed to Greece, and results are generally back in two weeks from the day the sample is mailed. At this time, the treatment protocol can be altered if necessary, based on the test results obtained.